MariMed Statistics
Total Valuation
MariMed has a market cap or net worth of 29.83 million. The enterprise value is 119.00 million.
| Market Cap | 29.83M |
| Enterprise Value | 119.00M |
Important Dates
The next estimated earnings date is Wednesday, November 11, 2026.
| Earnings Date | Nov 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
MariMed has 403.04 million shares outstanding. The number of shares has increased by 3.31% in one year.
| Current Share Class | 403.04M |
| Shares Outstanding | 403.04M |
| Shares Change (YoY) | +3.31% |
| Shares Change (QoQ) | +0.54% |
| Owned by Insiders (%) | 10.82% |
| Owned by Institutions (%) | 0.24% |
| Float | 335.80M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.18 |
| PB Ratio | 0.59 |
| P/TBV Ratio | 5.46 |
| P/FCF Ratio | 3.72 |
| P/OCF Ratio | 3.22 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 9.97, with an EV/FCF ratio of 14.86.
| EV / Earnings | n/a |
| EV / Sales | 0.73 |
| EV / EBITDA | 9.97 |
| EV / EBIT | n/a |
| EV / FCF | 14.86 |
Financial Position
The company has a current ratio of 0.92, with a Debt / Equity ratio of 1.81.
| Current Ratio | 0.92 |
| Quick Ratio | 0.25 |
| Debt / Equity | 1.81 |
| Debt / EBITDA | 7.60 |
| Debt / FCF | 11.32 |
| Interest Coverage | -0.23 |
Financial Efficiency
Return on equity (ROE) is -24.19% and return on invested capital (ROIC) is -1.38%.
| Return on Equity (ROE) | -24.19% |
| Return on Assets (ROA) | -0.58% |
| Return on Invested Capital (ROIC) | -1.38% |
| Return on Capital Employed (ROCE) | -1.40% |
| Weighted Average Cost of Capital (WACC) | 8.13% |
| Revenue Per Employee | 189,169 |
| Profits Per Employee | -17,267 |
| Employee Count | 923 |
| Asset Turnover | 0.82 |
| Inventory Turnover | 2.79 |
Taxes
In the past 12 months, MariMed has paid 4.74 million in taxes.
| Income Tax | 4.74M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -49.65% in the last 52 weeks. The beta is 1.36, so MariMed's price volatility has been higher than the market average.
| Beta (5Y) | 1.36 |
| 52-Week Price Change | -49.65% |
| 50-Day Moving Average | 0.07 |
| 200-Day Moving Average | 0.08 |
| Relative Strength Index (RSI) | 45.74 |
| Average Volume (20 Days) | 599,582 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.05 |
Income Statement
In the last 12 months, MariMed had revenue of 163.82 million and -14.95 million in losses. Loss per share was -0.04.
| Revenue | 163.82M |
| Gross Profit | 58.37M |
| Operating Income | -1.86M |
| Pretax Income | -10.18M |
| Net Income | -14.95M |
| EBITDA | 9.82M |
| EBIT | -1.86M |
| Loss Per Share | -0.04 |
Balance Sheet
The company has 6.54 million in cash and 90.68 million in debt, with a net cash position of -84.14 million or -0.21 per share.
| Cash & Cash Equivalents | 6.54M |
| Total Debt | 90.68M |
| Net Cash | -84.14M |
| Net Cash Per Share | -0.21 |
| Equity (Book Value) | 50.18M |
| Book Value Per Share | 0.11 |
| Working Capital | -5.32M |
Cash Flow
In the last 12 months, operating cash flow was 9.27 million and capital expenditures -1.26 million, giving a free cash flow of 8.01 million.
| Operating Cash Flow | 9.27M |
| Capital Expenditures | -1.26M |
| Depreciation & Amortization | 11.68M |
| Net Borrowing | -4.87M |
| Free Cash Flow | 8.01M |
| FCF Per Share | 0.02 |
Margins
Gross margin is 35.63%, with operating and profit margins of -1.14% and -9.13%.
| Gross Margin | 35.63% |
| Operating Margin | -1.14% |
| Pretax Margin | -6.21% |
| Profit Margin | -9.13% |
| EBITDA Margin | 5.99% |
| EBIT Margin | -1.14% |
| FCF Margin | 4.89% |
Dividends & Yields
MariMed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.31% |
| Shareholder Yield | -3.31% |
| Earnings Yield | -50.14% |
| FCF Yield | 26.86% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
MariMed has an Altman Z-Score of -0.03 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.03 |
| Piotroski F-Score | 3 |